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Investigators Explore Role of Oncogenes
in Normal Growth and Carcinogenesis
(Editor's Note: Jordan U. Gutterman, MD, chief of the Biological Therapy Section, Department of Clinical Immunology and
Biological Therapy, and Edwin C. Murphy, Jr, chief of the

Virology Section, Department of Tumor Biology, here answer
OncoLog's questions about their oncogene research and its
applications to patient care. Working with them on this research
project are assistant internists Mark Blick, DO, and Raze/le
Kurzrock, MD, both of the Department of Clinical Immunology
and Biological Therapy, and research associate Gary Gallic/(,
PhD, of the Department of Tumor Biology.)

What Is an _oncogene?
Gutterman: An oncogene is a gene that appears to code for
protein products involved in normal growth and maturation or
differentiation of all cells. By a variety of different mechanisms,
oncogenes can be aberrantly expressed ; this aberrant expression can be tumorigenic.

How were oncogenes discovered?
Murphy: J. Michael Bishop and Dominic Stahelin at the University of California in San Francisco around 1970 first set out to
locate the transforming gene within the genome of Rous sarcoma
virus (RSV), an RNA tumor virus. After finding the transforming
region of the viral genome and making DNA copies of that region
using reverse transcriptase, they decided to hybridize these DNA
copies or probes to the cellular DNA of normal chickens and
chickens infected with RSV. As expected, the probe hybridized to
infected chicken DNA; unexpectedly, it also hybridized to normal
chicken RNA. This finding indicated the presence of homologues
of retroviral transforming genes in normal cells.
We now know that RSV contains an src oncogene that is also
found in normal host cells. Cellular oncogenes, called protooncogenes, have a normal function in the normal cell and are
present in all vertebrates and some invertebrates as tar down the
evolutionary scale as yeast. By elaborate cellular gymnastics
similar to any recombination method, oncogenes were probably
originally "kidnapped" from normal animal cells by RNA tumor
viruses and became permanent components of the viral
genomes. The fact that oncogenes serve no function in the life
cycle of the virus lends support to this theory. This kidnapping
process is called transduction.
Are oncogenes then named after the retrovirus In which they
have been found?

Murphy: Yes. Src is named for RSV, for example, erb for avian
erythroblastosis virus, myb for avian myeloblastosis virus, myc
for avian myelocytomatosis virus, and fes for feline sarcoma
virus. These are only a few. Twenty to thirty oncogenes have
been found in and named for different viruses. These three-letter
acronyms also apply to the same oncogenes found in the normal
cellular genome. Oncogenes are simply easier to discover in
viruses that are known to be tumor causing than in normal cells
and, therefore, were initially named after the virus in which they
were found. There may be other oncogenes that have not yet
been discovered because they haven't been incorporated into
retroviruses.
What distinguishes an RNA tumor virus?
Murphy: An RNA tumor virus, which may or may not contain
oncogenes, is unique in its possession of an enzyme called
reverse transcriptase (RT) that reverses the flow of genetic
information, which normally proceeds from DNA to RNA, in cells
infected by the virus. Because of this reverse action, the RNA
tumor virus is also called a retrovirus. Each retrovirus contains
two identical strands of RNA. RT allows the genetic instructions
embodied in the viral RNA to be integrated into the DNA of the
infected host cell. The host cell may then manufacture new virus
particles; in addition, the DNA copy of the virus genes becomes a
permanent part of the cell's genome. Those retroviruses containing oncogenes have been found to have greater tumorigenic
potential. DNA tumor viruses also contain genes that cause
tumors, but there is no normal host gene that corresponds to
transforming genes found in DNA viruses. Unlike oncogenes of
the RNA tumor viruses, oncogenes of the DNA tumor viruses
have a defined function in the life cycle of the virus.

~

Speclflcally, what are some of the functions at oncogenes
normal cellular growth?
Gutterman: Some cellular oncogenes may be involved only
during early embryogenesis and then are shut off, but others
function continuously during the normal regulation of the cell
cycle. The myc and ras oncogenes are probably quite important
during normal metabolism, for example. Cellular oncogenes are
almost certainly involved in differentiation. Certain oncogenes are
only activated in specific tissues.
Continued on page 2
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Murphy: A recent study showed that in many different species
almost all cells express the ras oncogene at all times. The p21
product of the ras oncogene contains an enzyme, guanosine
triphosphatase (GTPase), that is crucial to the action of adenylcyclase, another enzyme that generates cyclic adenosine monophosphate, or cyclic AMP. Cyclic AMP transmits signals from the
outside to the inside of a cell, making it extraordinarily important
for communication between a cell and its environment. The c-sis
oncogene has been- shown to be related to platelet-derived
growth factor; the erb oncogene, structurally similar to the
epidermal growth factor receptor, is highly expressed during
b\ood vessel formation. A number of oncogenes are known to be
tyrosine kinases, enzymes also associated with epidermal growth
factor and thus key elements in growth control. Some oncogene
products are known to be nuclear proteins, such as myc, myb,
and fos. Fo~, originally found in murine osteosarcoma virus, is
highly expressed in hematopoietic tissue. Each oncogene product, whether a growth factor, a receptor, or a tyrosine kinase,
most likely has only one function, as do other proteins in general.
How are oncogenes Involved In carcinogenesis?
Gutterman: Tumorigenesis by retroviral infection is one mechanism we have already discussed, although this may be rare in
human cancers. Retroviruses, as well as other viruses, by
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inserting viral elements into a chromosomal segment adjacent to
an oncogene, may cause aberrant oncogene expression and
result in malignant transformation. Three other mechanisms of
carcinogenesis occur more frequently. One of these is
chromosomal translocation in which segments of chromosomes
change positions. Such an aberrancy is more common in
leukemias and lymphomas. For example, in chronic myeloid
leukemia (CML) a piece of chromosome 9 is translocated to
chromosome 22. There is a reciprocal translocation of a piece of
chromosome 22 to chromosome 9. The rearranged chromosome
22 segment is termed the Philadelphia chromosome (Ph 1 ). We
now know that the sis and ab/ oncogenes are on chromosomes
1
22 and 9, respectively, and are reciprocally translocated in Ph positive CML. The ab/ oncogene is probably involved in normal
growth and differentiation in certain tissues. In Burkitt's lymphoma, a portion of chromosome 8 containing the myc oncogene
shifts to chromosome 14. The cause of the regular occurrence of
such translocations is unknown. Viruses or movable genetic
elements similar to transposons found in bacteria may be
involved. As far as I know, in every known translocation associated with human cancer, one or more oncogenes is involved.
Another mechanism of carcinogenesis is mutation (i.e., an
alteration in the structure of the genes). Mutation is common in
the ras family of oncogenes. A change in certain amino acid
subunits of the ras p21 protein leads to a gene product that
possesses drastically reduced GTPase activity and is highly
transforming. We don't know the incidence of oncogenic mutation. By assays currently available, scientists have found that
about 15% of solid tumors have a mutation in the ras oncogene
that allows the gene, normally involved with growth, differentiation, or regulation, to become a transforming gene.
The third carcinogenic mechanism of oncogenes is amplification in which 10, 50, or even 100 copies of the gene are
produced. Consequently, the cell is flooded with an excess
amount of protein, causing the cell to divide indefinitely. Amplification of c-myc, for example, has been found in promyelocytic
leukemia and in colon carcinoma cell lines.

Can a single oncogenlc mechanism produce a tumor? ··
Gutterman: Most probably a combination of mechanisms is at
work in the different stages of development of cancer. Cooperation between two or maybe even three oncogenes may be
required to create a malignancy. A mutation of an oncogene may
be followed by amplification of a second oncogene and then
perhaps translocation of a third gene. Several such mechanisms
may be involved in some connecting fashion, but the fundamental
--............-.~
mt,:s:sa-geis1hat a variety of molecular changes occurs in these
oncogenes that causes them to lose their normal control mechanisms and so lead to malignancy.

Murphy: In culture, certain oncogenes, such as the ras genes,
are able to transform cells while others, like the myc gene, are
nontransforming but are able to immortalize cells. These results
imply that specific oncogenes have certain functions that are
involved in different facets of tumorigenesis.

Continued on page 3
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Lung Cancer Surpasses Breast Cancer
as Mortality Risk to Texas Women
Since 1983 lung cancer has been claiming the lives of more
Texas women than breast cancer, historically women's biggest
cancer threat. In 1983 in Texas, 1,895 women died of lung cancer
and 1,785 died of breast cancer.
According to Vincent Guinea, MD, chairman of UT MDAH's
Department of Patient Studies, the lung cancer mortality rate for
Texas women nearly doubled between 1970 and 1982, jumping
from 11.9 cases per 100,000 women in 1970 to 22.6 cases per
100,000 women in 1982 and increasing from 9.7% to 17.4% the
proportion of deaths from malignant neoplasms attributed to lung
cancer. Breast cancer mortality rates during this same time
remained stable.
Texas is one of nine states in which the number of lung cancer
deaths for women has outpaced breast cancer deaths. In the
United States as a whole, breast cancer is still the leading cause
of death in women, but the American Cancer Society estimates
that in 1986 the lung cancer death rate for women will surpass
that of breast cancer to become the leading killer of women
nationwide.
Two reasons account for the state's being one of the first to
have the number of lung cancer deaths surpass the number of
breast cancer deaths. First, Texas has a higher than average
incidence of lung cancer. Scientists blame the higher rate on
Texas's broad coastal area because of the environmental factors
and cancer-causing exposures related to industry typically found
in coastal areas. But Guy A. Newell, MD, chairman of the
Department of Cancer Prevention, thinks that far more significant
is the high concentration of Hispanic people in Texas. Because
Hispanic women have a substantially lower incidence of breast
cancer than do white women, the incidence of breast cancer is
lower overall in Texas. Therefore, in Texas the lung cancer
mortality rate would have a narrower than average gap to close in
meeting and surpassing the breast cancer mortality rate.
Unfortunately, survival rates for lung cancer are poorer than
those for breast cancer. Based on cases diagnosed 1973-1980,
the National Cancer Institute reports a relative five-year survival
rate of 74% for patients with breast cancer, but for patients with
lung cancer the relative five-year survival rate is only 12%.
Because 85% of lung cancer cases are attributable to cigarette
smoking, the increase in lung cancer mortality rates in women
can be largely attributed to the increase in the number of women
who smoke. During the years of World War .11, the number of
women smokers increased considerably, and with each successive birth cohort the number of female cigarette smokers has
increased. Although the proportion of males who smoke has
historically been higher than that of females who smoke, now
there are more adolescent girls who smoke (12.7%) than there
are adolescent boys who smoke (10.7%). Adding to this effect is
the fact that fewer women than men are quitting: according to
prevalence statistics, the percentage of men smoking dropped
14.4% between 1965 and 1980, but the percentage of women
smoking dropped only 4.4%.
Vol. 30, No. 1
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Fig. 1. Texas lung cancer and breast cancer mortality rates for
women, 1970-1982. Rates are adjusted by age to the 1970 U.S.
population. (Adapted from Morbidity and Mortality Weekly Report 33: 267, 1984)

Newell predicts a very bright future potential for having a
society free of smokers, and because of this he supports an
aggressive preventive approach. He suggests that the physician
follow the model outlined by Lichtenstein and Danaher in Chronic
Obstructive Lung Disease: Clinical Treatment and Management
(edited by A. E. Brashear and M. L. Rhodes): (1) be a
nonsmoking, healthy life-~tyle model; (2) supply information on
the risks of smoking and their reduction after quitting; (3)
encourage quitting; (4) refer patients to smoking cessation
programs; and (5) recommend specific strategies for quitting and
follow up to provide reinforcement.

Oncogenes
Continued from page 2
How Is the RNA expression of a partlcular oncogene Identified and measured In certain tumors?
Murphy: Generally, one does this by measuring the amount of
radiolabeled oncogene DNA probe that can hybridize to RNA
obtained from tumor tissue. In practice, total cellular RNA is
prepared from the tumor tissue and the messenger RNA (mRNA)
class of RNA species is isolated from this mixture. The RNA can
then be separated into discrete classes by size by electrophoresis in agarose gels, transferred to nitrocellulose filters,
and hybridized to radiolabeled probes derived from retroviral
oncogenes or from human proto-oncogenes that have been
molecularly cloned based on their homology with the retroviral
Continued on page 4
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New NCI Data Base Offers Physicians
Up-to-Date Cancer Treatment Information
Physician's Data Query (PDQ), a new computerized cancer
information bank, is putting National Cancer Institute (NCI)
guides to diagnoses, protocols, and treatment centers at the
fingertips of physicians who operate computer terminals.
Developed by the NCI and introduced to physicians by
teleconference early this year, PDQ breaks down the information
it offers into three categories:
• state-of-the-art information on prognosis and treatment for
about 80 different types of cancers
• protocols from more than 1,000 active clinical trials
• a directory of physicians and organizations that care for patients
with cancer.
Vincent T. DaVita, Jr, MD, director of NCI, introduced the
system. "This is an experiment to reduce mortality," DaVita said,
explaining that a major goal of the system is to save lives.

To access PDQ, a user needs a terminal that has a screen
width of at least 80 characters and a modem. Users must pay a
$50 one-time registration fee, and a monthly minimum charge is
levied but applicable toward usage charges. The user's fee varies
depending on whether the system is accessed during prime or
nonprime hours. PDQ is accessible 22 hours per day Monday
through Friday and 13 hours on Saturday.
(Physicians who desire further information should write PDQ
Information Coordinator, National Cancer Institute, A. A. Bloch
International Cancer Information Center, Building 82, Rm. 105,
9030 Old Georgetown Road, Bethesda, MD 20205-ED.)

Oncogenes
Continued from page 3

The PDQ cancer information system holds prognostic and
oncogenes. If a particular RNA species bound to the filter is
treatment information on all major types of cancer. Each of these
complementary to the DNA probe being used, the DNA probe will
types is described in a capsule statement and a longer general
specifically hybridize to this RNA and survive the washing
summary. Summaries include prognosis, relevant staging and
procedure designed to remove unhybridized probe. X-ray film is
cellular classification systems, and comparable treatment options
finally exposed to the filter. The position and intensity of the signal
considered state-of-the-art treatment by type, stage of disease,
observed will yield information on the size and amount .of an
or both.
oncogene mRNA in a given tissue.
More than 1,000 active treatment protocols, which are updated
monthly, are included on PDQ. These are protocols directly
Are all tumors the result of aberrant oncogenlc expression?
supported by NCI or submitted for inclusion in the PDQ data base
by clinical investigators nationwide.
Murphy: I don't know the answer to that, but I don't think it is
About 10,000 physicians who devote a major portion of their
coincidental that in almost every case the known oncogenes
clinical practice to treating cancer patients are listed by name,
seem to be involved with chromosome translocation . Also
address, and telephone number in the PDQ directory, but DaVita
significant is that, of the very large number of genes in the human
said that being listed does not constitute an NCI endorsement.
Along with the physicians are listed the names, addresses, and
genome, only the 25 to 30 known to be involved in malignancy
telephone numbers of about 2,000 institutions and health care
are found in acutely transforming retroviruses, usually in a
organizations involved in cancer patient care. Both sets of names
mutated form. Such evidence suggests that transformation may
are indexed geographically.
result from an upset in the normal functioning of the oncogenes.
This does not suggest, however, that altered oncogenes are
The protocol file was written and refined with the help of more
solely responsible for tumorigenesis.
than 400 cancer specialists. Seventy-two medical, surgical,
pediatric, and radiation oncologists serve as members of an
Is Information obtained from oncogene research being used
editorial board and as consultants responsible for keeping PDQ
at UT MDAH to treat patients?
up-to-date. UT MDAH's Eleanor D. Montague, MD, deputy
chairman of the Department of Radiotherapy, and Oscar M.
Guillamondegui, MD, deputy chairman of the Department of
Gutterman: We hope that eventually the answer will be yes. The
Head and Neck Surgery, serve as consultants.
therapeutic aspects of our oncogene program with fresh human
- - ~ I---o make PDQ availahJa.cornroeccially, NCI has~oi......
oe.,.d.,_w-ithH-U-th_..._e,______ _~ tu....m
. . . ......
or,_,. sc____,a
....r'-""'e'------""'be~g:,.ui._...n nL.lli.....,
ngtt_.t....,o_____.co.,., _.m_._._,_,_e_Jt. . ,oM'ge.. . ,t. _.b-eLL
r _JMLILl.l,Aa._.,
rk._____.B,__.._l
_. ....ic k~,______._.R_u.az~e=ll,. . e'----partnership of W. B. Saunders, the world's largest medical book
Kurzrock, and I are specifically studying the regulation by
publisher, and BAS (Bibliographic Retrieval Services), the cominterferon of oncogenic expression in CML, chronic lymphocytic
pany supplying the National Library of Medicine's MEDLINE, a
leukemia, acute leukemias, and other tumors. Interferons that are
medical literature on-line interactive bibliographic searching and
available for use in the clinic are potent antigrowth substances
retrieval system. BAS/Saunders calls the data base service
and are regulatory agents of differentiation in the body. Alpha"Colleague," and it includes other information besides PDQ, such
interferon, for example, is an important inhibitor of several growth
as the full text of more than 15 books and four journals, including
factors, including epidermal growth factor, platelet-derived
The New England Journal of Medicine, and abstracts and
growth factor, and sarcoma growth factors. Alpha- and gammaindexes, including MEDLINE.
Continued on page 5

4

January-March 1985

THE UNIVERSITY OF TEXAS SYSTEM CANCER CENTER
M. D. ANDERSON HOSPITAL AND TUMOR INSTITUTE

Oncogenes
Continued from page 4
interferon probably regulate different oncogenes. We are getting
excellent results with alpha-interferon in the control of excess
growth of white blood cells in the benign phase of Ph 1 -positive
CML. As I said previously, translocation of the c-abl oncogene is
characteristic of Ph 1 -positive CML. The product of the ab/
oncogene has a particular protein kinase activity. We're now
testing whether interferon can regulate the aberrant expression of
that oncogene, shut down or dampen the excess enzymatic
activity that probably allows these white cells to proliferate
excessively.
What other substances have you used, or do you plan to
use, In the cllnlc to regulate oncogene expression?
Gutterman : Retinoic acid and other biologic substances like the
interferons might be used to regulate the expression of certain
oncogenes. Recent evidence shows that as certain tumor cell
lines in culture mature in the presence of retinoic acid, the
expression of certain oncogenes decreases. The same thing
happens with gamma-interferon and vitamin D. But it is not clear
whether these substances first allow the cells to differentiate and
so shut off the oncogenes or the substances shut the oncogenes
off, allowing the cells to mature normally. The myc oncogene is
down-regulated (i.e., has decreased RNA expression) by alphainterferon in a Burkitt's lymphoma cell line. These changes
precede the antigrowth effects of alpha-interferon. I am sure
many chemotherapeutic agents work to control oncogenes,
particularly those that come from natural products, from plants
like vinca alkaloids or antibiotics. Perhaps these substances are
in plants for the same reason, to regulate growth and differentiation. Plants also have oncogenes and develop tumors. Though
certain chemotherapeutic agents probably work through the
control of oncogenes, attention is now focused on the interferons
and vitamins.
Is the therapeutic use of monoclonal antibodies to turn off
aberrant oncogene expression a posslblllty?

evidence in patients that the change in expression of an
oncogene by any agent is associated with regression of a tumor.
We have results that suggest this possibility in certain tumors, as
in the Daudi cell line of Burkitt's lymphoma. The myc gene is
involved in the uncontrolled growth of these tumor cells in tissue
culture. Scientists have used interferon to shut off the expression
of the myc oncogene within about three or four hours and have
observed a delay in growth a day or two later. This evidence
suggests that interferon probably is involved in the shutting off of
growth in tissue culture, possibly through its effect on expression
of an oncogene.
Murphy: It is really not clear yet whether tumor regression
necessarily involves a decrease in oncogene expression. In
Gallick's and Kurzrock's work at UT MDAH with colon carcinoma,
metastatic lesions in the lungs appear to have a decreased
expression of ras relative to the adjacent normal tissues and the
primary tumor. The ras protein expression is inordinately depressed in metastatic colon cancer lesions. This seems to
suggest that the oncogene does select for a cell type. It could be
that metastatic cells are no longer sufficiently differentiated in that
they have lost their specific tissue type to the extent that they no
longer require ras expression. Or perhaps in an early stage of the
tumor, ras was overexpressed and became toxic; the only cells to
survive and metastasize may have been those that produced less
ras. Again, to investigate these theories we need to study the
molecular events that occur.
Dr Gutterman, you mentioned In another Interview the
possibility of eventually defining tumors by their molecular
profile and basing treatment on this profile. Please explain
briefly.
Gutterman: We are beginning to define tumors on a molecular
basis, for example, in CML, lymphomas, and other tumors. If we
know which oncogene or oncogenes and growth factors are
involved in the growth of a patient's tumor, we may be able to use
inhibitors of such oncogene products. For example, the ras gene
is known to be mutated and thus aberrantly expressed in a small
pecentage of cancers of the colon, lung, bladder, and other solid
tumors. Fifteen percent of solid tumors are thought to have a

Gutterman: Yes, for both diagnostic and therapeutic purposes
mutation of the ras gene producing an amino acid change. That
we hope to use monoclonal antibodies in our work with onmutation causes overexpression of the ras protein product p21,
cogenes. Any oncogene protein or growth factor receptor that is
and overexpression of p21 is highly transforming. There is recent
on the cell surface may be located or possibly regulated by
evidence that alpha-interferon can inhibit the production of the
monoclonal antibodies. The oncogene protein erb-B is located on
nonmutated protein when excessive in certain mouse tumor cells
chromosome 7, where the epidermal growth factor receptor is. It
and can actually cause a phenotypic reversion. The transformais, in fact, part of the epidermal growth factor receptor. But erb-B
tion or malignant process can be reversed in tissue culture with
- -can-be-overly-expressed in-certain-tumors and may be-involve·d. . __ _____..intederorLb)cshutting_off the- overexpr-ession oLtbis- oncogeae__ _
with excessive growth. Monoclonal antibodies to the epidermal
So, theoretically, colon cancer, if partially caused by an excess
growth factor receptor have been developed.
production of the ras oncogene protein, might be reversed or
controlled with interferon if the cancer were detected early
enough. We don't know if this is possible in humans, but it has
Have you found any parallels between a decrease in oncogene expression and tumor regression?
been shown in tissue culture and in animals.
Gutterman: We are studying that at present. Another group may
have shown this in patients with CML. The ab/ gene product was
shut off by interferon and the patient went into remission. But
there is no proof that the cause of the remission was the change
in the expression of the oncogene. In fact, there is no clear
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Murphy: In Burkitt's lymphoma, the translocated myc oncogene,
which in its normal location is extremely important in normal
growth, has lost its normal control mechanisms and continues to
be transcribed. It was reported about six months ago that betaContinued on page 6
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Continued from page 5

interferon is a potent inhibitor of the expression of the myc
oncogene and of the growth of lymphoma cells. This natural
substance stops myc expression when myc has lost its normal
control mechanism, which is probably the effect of the action of
another protein. This is an example of the effect oncogene
research may have on the direction of cancer treatment. Rather
than nonspecifically treat cancer, we are going to approach the
disease on a molecular basis in the next decade.
Gutterman: I suspect that one day we will have specific inhibitors
for each of these oncogenes. Each oncogene must be controlled
by natural mechanisms; otherwise, cells would go awry. That is,
there are natural antioncogene proteins. One day we will know
the specific sequences of these substances that naturally regulate certain oncogenes and may be able to use these proteins in
therapy to regulate aberrant oncogene expression. In addition,
characterizing cancers molecularly should aid in diagnosis and in
monitoring patients during and after treatment.

If, as you stated previously, more than one oncogene growth
factor Is Involved In malignant transformation, how wlll this
affect future therapy?
Gutterman: It is not clear whether these growth factors work in
sequence in different stages of disease or work together.
Therapeutically, we're going to have to use several antigrowth
factors, such as the interferon family, either consecutively or in
combination to shut off different parts of the cycle that produce
aberrant oncogene expression.
Murphy: As we have learned more about the 25 to 30 oncogenes
identified so far, the problem they pose has become as complex
as the inside of an atom. In the past four or five years an
incredible number of growth-promoting or -altering substances
have been found in and among cells. Cells are communicating
with themselves and each other all the time. In this complex
communication network, genes are likely to be turned on and off
by different substances. Oncogene research is still an extremely
open field with many dark comers. It may be best to focus our
study on the enormous number of environmental stresses or
stimuli affecting the relatively few number of known oncogenes to
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understand the cellular mechanisms involved in tumorigenesis
and to find the appropriate sequence or combination of substances to shut it off.
Gutterman: In the clinic we're beginning to test the first really
significant combination of natural antigrowth substances with
alpha- and gamma-interferon. This work is independent of the
oncogene program, but in diseases whose oncogene expression
we can measure, as in the chronic leukemias or other tumors of
blood, we will be studying oncogene expression simultaneously.
What unique contribution Is UT MDAH making In oncogene
research?
Murphy: Our oncogene program is unique in that we have the
clinical resources to do research more relevant to the problems
oncogenes are causing in patients. We are able to study
oncogene expression in fresh human tumor biopsy specimens
instead of in tissue culture materials, which are easier to work
with but may present an unrealistic experimental situation. My
laboratory is involved in the generation, purification, and preparation of probes for 10 to 12 different oncogenes that are being
used to study the expression and structure of proto-oncogenes in
fresh primary or metastatic human tumor samples. We have had
to overcome great technological barriers to work with fresh
samples, but the advantage of this approach is that we are better
able to understand the real situation in the cancer patient. As a
result, we have begun to make substantial advances.
Gutterman: This collaboration between clinicians and researchers fuels progress in the laboratory and the clinic. Information
obtained from oncogene research helps to identify substances,
such as alpha-interferon, gamma-interferon, or retinoic acid, that
may inhibit tumor growth or induce cell differentiation through
effects on oncogenes. Patient response to these substances may
provide a clue to understanding the complex network of communication in and among cells and to discovering tumorigenic
aberrancies in this network.
(Physicians who desire additional information should write
Jordan U. Gutterman, MD, chief of the Biological Therapy
Section, Department of Clinical Immunology and Biological
Therapy, Box 41, or Edwin C. Murphy, Jr, PhD, chief of the
Virology Section, Department of Tumor Biology, Box 108, The
University of Texas M. D. Anderson Hospital and Tumor Institute
at Houston, 6723 Bertner Avenue, Houston, Texas 77030--Eo.)
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